Does HbA1c tell me anything about hepatic fat on tirzepatide?

Concretely: HbA1c · tirzepatide.

This is one of those things that everyone repeats and nobody derives.

This matters practically, not just academically, because it changes what I would do next.

What is the causal chain, and where does it stop being established?

Start with the pattern. A hepatocellular pattern with alanine aminotransferase above aspartate aminotransferase points one way; a cholestatic pattern with alkaline phosphatase and gamma-glutamyl transferase points another.

Hy's law describes the combination that matters: transaminases above three times the upper limit together with bilirubin above twice the upper limit and no cholestatic explanation. That combination is a signal; isolated mild transaminase elevation is not.

Weight loss of ten per cent or more typically reduces transaminases substantially in people whose elevation was driven by hepatic fat, which is the majority of mild elevations in this population.

Trials in this class have generally reported improvement rather than deterioration in liver biochemistry, consistent with the weight-mediated mechanism.

Read the pattern before the magnitude, and the magnitude in multiples of the upper limit.

Answering this needs the magnitude in multiples of the upper reference limit, because the thresholds that matter clinically are defined that way and not in absolute units.

Very rapid weight loss can transiently worsen liver biochemistry, which is one of several arguments against pursuing the steepest possible trajectory.

Creatine kinase, alkaline phosphatase and bilirubin together tell you which compartment the abnormality is in, and ordering the transaminases alone throws that information away.

Hy's law and its variants are the standard framework for identifying drug-induced liver injury in trials and are why bilirubin is measured alongside transaminases rather than instead.

Attributing an enzyme change to a compound requires a baseline, and most people asking have not got one.

Transaminases plus bilirubin plus alkaline phosphatase, or you have not measured enough to conclude anything.

edited 10 Feb 2025 by lipid_panel_q — added the placebo-arm figures

Answer first: mild transaminase elevation is common in this population before any drug is involved, and the usual cause is hepatic steatosis rather than anything acute.

Reference upper limits around forty units per litre for ALT are conventional rather than physiological; several groups have argued for limits closer to thirty for men and twenty-five for women.

An isolated result three weeks after starting anything is difficult to interpret. A baseline taken before starting makes the same result trivially interpretable, which is the argument for baselines.

Research-use material of unknown content is an unquantifiable variable in any such attribution.

Get a baseline before you start anything, because it converts an uninterpretable result into an interpretable one for the cost of one blood draw.

This is one of the areas where the trend across several measurements is far more informative than any single result.

Gamma-glutamyl transferase is sensitive and unspecific: it rises with alcohol, with several medications and with fatty liver, and an isolated elevation rarely changes anything on its own.

Laboratory-specific reference intervals for transaminases vary enough that cross-laboratory comparison of borderline values is unreliable.

Isolated mild elevation is common and usually improves with weight loss.

The relevant caution is that a rapid rise, particularly with bilirubin, is a different event from a stable mild elevation and needs handling differently.

Alanine aminotransferase is relatively liver-specific; aspartate aminotransferase is also present in muscle, heart and red cells. A raised AST with a normal ALT after heavy resistance training is usually muscle, and creatine kinase settles the question.

Population data show a substantial fraction of adults with mild transaminase elevation attributable to hepatic steatosis, which sets the base rate against which any new finding should be read.

Nothing here is medical advice. An abnormal result needs somebody who can take a history and examine you.

New training, alcohol and over-the-counter products first. Then the interesting hypotheses.